Prior alcohol consumption does not impair HCV treatment
For patients with hepatitis C virus treated with pegylated interferon-alpha and ribavirin, drinking patterns and the amount of alcohol consumed before treatment do not impact treatment success, according to a study published in the October issue of Hepatology.
(HealthDay)—For patients with hepatitis C virus (HCV) treated with pegylated interferon-alpha and ribavirin (P/R), drinking patterns and the amount of alcohol consumed before treatment do not impact treatment success, according to a study published in the October issue of Hepatology.
Marcia Russell, Ph.D., from the Pacific Institute for Research and Evaluation in Berkeley, Calif., and colleagues examined the effect of alcohol on treatment outcome in 421 treatment-naive HCV-positive patients, who were members of an integrated health care plan and were treated with P/R. For 259 of the patients, a detailed drinking history was obtained.
The researchers found that, before HCV diagnosis, regular drinking was reported by 93.1 percent of patients. Between HCV diagnosis and treatment, 30.9 percent reported regular drinking, and this dropped to 1.9 percent during treatment and 11.6 percent after the end of treatment. Before starting treatment, 67.9 percent reported heavy drinking patterns, with 63.5 percent drinking more than 100 kg of ethanol, while 29.3 percent reported abstaining less than the requisite six months before initiation of treatment. In spite of these patterns, 80.2 percent of patients with HCV genotype 2 or 3 and 45.1 percent with genotype 1, 4, or 6 had a sustained virological response (SVR). Neither pretreatment drinking patterns nor total alcohol intake was related to SVR rates. Lower SVR rates were seen in moderate, but not heavy, drinkers who abstained for less than six months before treatment.
"These findings suggest that past heavy drinking and recent drinking represent low treatment risk in these patients," the authors write.
One author disclosed financial ties to Merck.
More information: Abstract
Full Text (subscription or payment may be required)
Journal reference: Hepatology
Copyright © 2012 HealthDay. All rights reserved.
- Quadruple therapy shows 100 percent SVR for HCV patients previously unresponsive to treatment Apr 02, 2011 | not rated yet | 0
- Treating hepatitis C infection in prison is good public policy Sep 27, 2012 | not rated yet | 0
- Coffee drinking improves hepatitis C treatment response Jun 07, 2011 | not rated yet | 0
- The future looks bright for HCV patients who have failed to respond to current treatments Apr 01, 2011 | not rated yet | 0
- Hypertension ups retinopathy risk with HCV treatment Aug 02, 2012 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Classical and Quantum Mechanics via Lie algebras
Apr 15, 2011 I'd like to open a discussion thread for version 2 of the draft of my book ''Classical and Quantum Mechanics via Lie algebras'', available online at http://lanl.arxiv.org/abs/0810.1019 , and for the...
- More from Physics Forums - Independent Research
More news stories
(HealthDay)—A shortage of a critical tuberculosis drug has hampered the efforts of health departments across the United States to contain the spread of the highly infectious lung disease, federal officials ...
Diseases, Conditions, Syndromes 15 minutes ago | not rated yet | 0
Maintaining a heart healthy lifestyle may also help protect chronic kidney disease patients from developing kidney failure and dying prematurely, according to a study appearing in an upcoming issue of the Journal of the Am ...
Diseases, Conditions, Syndromes 35 minutes ago | not rated yet | 0
Finnish researchers unveiled new data Thursday to link the Pandemrix flu vaccine to a higher risk of the sleeping disorder narcolepsy in adults.
Diseases, Conditions, Syndromes 1 hour ago | not rated yet | 0
A second child has contracted polio in a restive Pakistani tribal region near the Afghan border after the Taliban banned vaccinations there nearly a year ago, a UN official said Thursday.
Diseases, Conditions, Syndromes 1 hour ago | not rated yet | 0
Chinese and U.S. scientists have used virus isolated from a person who died from H7N9 avian influenza infection to determine whether the virus could infect and be transmitted between ferrets. Ferrets are often used as a mammalian ...
Diseases, Conditions, Syndromes 2 hours ago | not rated yet | 0 |
(Medical Xpress)—Regulating the distribution of power in neurons is done by a system that makes the national electric grid look simple by comparison. Each neuron has several thousand mitochondria confined ...
38 seconds ago | not rated yet | 0 |
Breast cancer characterized as "triple negative" carries a poor prognosis, with limited treatment options. In some cases, chemotherapy doesn't kill the cancer cells the way it's supposed to. New research from Western University ...
11 minutes ago | not rated yet | 0
Mayo Clinic researchers have used next generation genomic analysis to determine that some of the more aggressive prostate cancer tumors have similar genetic origins, which may help in predicting cancer progression. The findings ...
15 minutes ago | not rated yet | 0
Detection of HIV antibodies is used to diagnose HIV infection and monitor trials of experimental HIV/AIDS vaccines. New, more sensitive detection systems being developed use microspheres to capture HIV antibodies ...
12 minutes ago | not rated yet | 0
Don't doubt it when a woman harried by hot flashes says she's having a hard time remembering things. A new study published online in Menopause, the journal of The North American Menopause Society (NAMS), helps confirm with o ...
14 minutes ago | not rated yet | 0
(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...
55 minutes ago | not rated yet | 0